Genomic warfare to counter malaria drug resistance

Feb 16, 2010

Scientists battling malaria have earned a major victory. According to a Nature Genetics study, an international group of researchers has used genomics to decode the blueprint of Plasmodium falciparum - a strain of malaria most resistant to drugs that causes the most deaths around the world. The discovery may lead to advanced pharmaceuticals to fight the disease and prevent drug resistance among the 250 million people infected by malaria each year.

"Combating resistance is nothing short of an arms race," says lead author Dr. Philip Awadalla, a pediatrics professor at the Université de Montréal, a scientist at the Sainte-Justine University Hospital Research Center and scientific director of CARTaGENE. "As the malaria pathogen evolves, researchers must evolve with it to find ways to counter the disease."

The team decoded 200 malaria samples from Asia, Africa, Central America, South America and Papua New Guinea. Their goal was to identify how strains were becoming resistant to the eight anti-malaria drugs currently available.

"There are substantial genetic differences in malaria around the world," stresses Dr. Awadalla, noting African strains differ from Asia strains. "What has occurred is a combination of genetic drift, where genes segregated over space and time from differential environments, immune pressures and exposures to drugs."

As part of their genomic mapping, the research team found that Plasmodium falciparum recombined fastest in Africa. Dr. Awadalla compares malaria genomes to human genomes. In malaria, however, variation among some genetic material is so high and evolves so rapidly that the parasite can develop .

New clues garnered by this study, he says, "will allow pharmaceutical companies to create treatments that target the evolving malaria genome."

Explore further: Researchers develop model for better testing, targeting of malignant peripheral nerve sheath tumors

More information: The article "Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs" is published in the journal Nature. www.nature.com/ng/journal/vaop/ncurrent/full/ng.528.html

add to favorites email to friend print save as pdf

Related Stories

Discovery provides new drug targets for malaria cure

Jan 11, 2010

Researchers are a step closer to developing new antimalarial drugs after discovering the normal function of a set of proteins related to the malaria parasite protein, which causes resistance to the front-line drug chloroquine. ...

Malaria top killer in Congo

Apr 30, 2008

Health officials in the Democratic Republic of Congo say malaria is the primary cause of illness and death, despite prevention efforts.

Recommended for you

User comments : 0

More news stories

If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Changing cancer's environment to halt its spread

By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...